Mavorixafor was generally well tolerated as a monotherapy and in combination with G-CSF, with no drug-related serious adverse ...

And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), retaining the price target of ...

Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for ...

Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate ...

Both Big Pharma Sanofi and AI-focused biotech Formation Bio plan on using Muse in upcoming clinical trials, with an initial ...

Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...

The double-blinded, placebo-controlled study to assess safety and efficacy of R327G is set to begin mid-next month.

The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...